最新ニュース Danaher (NYSE:DHR) 株価情報

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Danaher Corp

DEUTSCHE EUROSHOP UNS/ADR by Deutsche Euroshop AG

Deutsche EuroShop AG

Investors with a lot of money to spend have taken a bullish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 37%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $747,642, and there was 1 call, for a total amount of $104,610.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $235.0 to $260.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Danaher's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Danaher's significant trades, within a strike price range of $235.0 to $260.0, over the past month.
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732129237_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$28.9</td>
<td>$28.4</td>
<td>$28.43</td>
<td>$260.00</td>
<td>$182.8K</td>
<td>1.6K</td>
<td align="right">136</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$29.7</td>
<td>$28.3</td>
<td>$28.41</td>
<td>$260.00</td>
<td>$154.1K</td>
<td>1.6K</td>
<td align="right">72</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$19.8</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$250.00</td>
<td>$152.8K</td>
<td>1.9K</td>
<td align="right">80</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$2.1</td>
<td>$1.9</td>
<td>$1.9</td>
<td>$235.00</td>
<td>$104.6K</td>
<td>557</td>
<td align="right">551</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$28.9</td>
<td>$28.5</td>
<td>$28.5</td>
<td>$260.00</td>
<td>$91.5K</td>
<td>1.6K</td>
<td align="right">212</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<h3>Where Is Danaher Standing Right Now?</h3>
<ul>
<li>With a volume of 1,313,444, the price of DHR is up 0.34% at $231.63. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>Expert Opinions on Danaher</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $305.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Danaher, maintaining a target price of $311. 
&#x2A; Reflecting concerns, an analyst from Stephens &amp; Co. lowers its rating to Overweight with a new price target of $315. 
&#x2A; An analyst from UBS persists with their Buy rating on Danaher, maintaining a target price of $305. 
&#x2A; An analyst from Wolfe Research upgraded its action to Outperform with a price target of $285. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Danaher with a target price of $310. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Danaher with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

What the Options Market Tells Us About Danaher

Investors with a lot of money to spend have taken a bearish stance on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DHR, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Danaher.
This isn't normal.
The overall sentiment of these big-money traders is split between 18% bullish and 81%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $574,327, and 2 are calls, for a total amount of $150,000.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $210.0 to $260.0 for Danaher over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Danaher stands at 431.56, with a total volume reaching 1,664.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Danaher, situated within the strike price corridor from $210.0 to $260.0, throughout the last 30 days.
<h3>Danaher 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731701829_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$11.5</td>
<td>$11.0</td>
<td>$11.2</td>
<td>$230.00</td>
<td>$163.5K</td>
<td>1.3K</td>
<td align="right">139</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.9</td>
<td>$4.3</td>
<td>$4.9</td>
<td>$230.00</td>
<td>$147.0K</td>
<td>1.1K</td>
<td align="right">300</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$44.8</td>
<td>$42.7</td>
<td>$44.1</td>
<td>$230.00</td>
<td>$110.2K</td>
<td>0</td>
<td align="right">25</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$0.95</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$210.00</td>
<td>$62.8K</td>
<td>126</td>
<td align="right">699</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$31.6</td>
<td>$30.2</td>
<td>$30.7</td>
<td>$260.00</td>
<td>$61.4K</td>
<td>205</td>
<td align="right">30</td>
</tr>
</tbody>
</table>

<h3>About Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
After a thorough review of the options trading surrounding Danaher, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Danaher</h3>
<ul>
<li>With a trading volume of 3,258,575, the price of DHR is down by -1.73%, reaching $235.23.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<h3>Expert Opinions on Danaher</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $288.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Danaher, which currently sits at a price target of $315. 
&#x2A; An analyst from Barclays persists with their Equal-Weight rating on Danaher, maintaining a target price of $275. 
&#x2A; An analyst from Baird persists with their Outperform rating on Danaher, maintaining a target price of $277. 
&#x2A; An analyst from Stifel persists with their Hold rating on Danaher, maintaining a target price of $265. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for Danaher, targeting a price of $310. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Danaher, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

WIIM

Danaher shares are trading lower after Third Point in a 13F disclosed that it decreased its stake in the company by 5%

News

Trading Ideas

AAPL

AMZN

MSFT

Third Point 13F Shows Decreased Stake In PG&E Corp By 7% From 53,750,000 To 49,750,000 Shares; Amazon By 27% From 5,100,000 To 3,700,000 Shares; Danaher Corp By 5% From 2,050,000 To 1,950,000 Shares; Vistra Corp By 29% From 4,470,000 To 3,175,000 Shares; Microsoft By 45% From 1,580,000 To 870,000 Shares; Meta Platforms By 50% From 1,100,000  To 545,000 Shares; TSM By 12% From 2,025,000 To 1,780,000 Shares; Apple By 52% From 1,950,000 To 930,000 Shares; Amphenol Corp By 43% From 2,800,000 To 1,600,000 Shares

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has fallen 5.68% since its last report. The company recently reported that it has 5.32 million shares sold short, which is 0.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730733432_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 5.39%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Danaher's Recent Short Interest

In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) in relation to its major competitors in the Life Sciences Tools &amp; Services industry. Through a detailed examination of key financial metrics, market standing, and growth prospects, our objective is to provide valuable insights and illuminate company's performance in the industry.
<h3>Danaher Background</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danaher Corp</td>
<td>46.75</td>
<td>3.49</td>
<td>7.74</td>
<td>1.62%</td>
<td>$1.66</td>
<td>$3.4</td>
<td>3.09%</td>
</tr>
<tr>
<td>Thermo Fisher Scientific Inc</td>
<td>34.98</td>
<td>4.36</td>
<td>5.06</td>
<td>3.38%</td>
<td>$2.91</td>
<td>$4.35</td>
<td>0.54%</td>
</tr>
<tr>
<td>Agilent Technologies Inc</td>
<td>28.46</td>
<td>6.66</td>
<td>6.19</td>
<td>4.65%</td>
<td>$0.43</td>
<td>$0.85</td>
<td>-5.62%</td>
</tr>
<tr>
<td>IQVIA Holdings Inc</td>
<td>27.48</td>
<td>5.45</td>
<td>2.52</td>
<td>4.17%</td>
<td>$0.8</td>
<td>$1.38</td>
<td>4.28%</td>
</tr>
<tr>
<td>Waters Corp</td>
<td>36.95</td>
<td>14.34</td>
<td>7.92</td>
<td>10.71%</td>
<td>$0.24</td>
<td>$0.42</td>
<td>4.02%</td>
</tr>
<tr>
<td>West Pharmaceutical Services Inc</td>
<td>46.96</td>
<td>8.33</td>
<td>8.15</td>
<td>5.1%</td>
<td>$0.21</td>
<td>$0.26</td>
<td>-0.07%</td>
</tr>
<tr>
<td>Avantor Inc</td>
<td>49.58</td>
<td>2.73</td>
<td>2.23</td>
<td>1.05%</td>
<td>$0.23</td>
<td>$0.56</td>
<td>-0.34%</td>
</tr>
<tr>
<td>Revvity Inc</td>
<td>75.65</td>
<td>1.90</td>
<td>5.52</td>
<td>0.7%</td>
<td>$0.22</td>
<td>$0.39</td>
<td>-2.45%</td>
</tr>
<tr>
<td>Bio-Techne Corp</td>
<td>79.27</td>
<td>5.59</td>
<td>10.32</td>
<td>1.6%</td>
<td>$0.07</td>
<td>$0.2</td>
<td>-5.44%</td>
</tr>
<tr>
<td>Medpace Holdings Inc</td>
<td>27.98</td>
<td>11.27</td>
<td>4.94</td>
<td>11.72%</td>
<td>$0.12</td>
<td>$0.17</td>
<td>8.29%</td>
</tr>
<tr>
<td>Charles River Laboratories International Inc</td>
<td>21.65</td>
<td>2.51</td>
<td>2.29</td>
<td>2.44%</td>
<td>$0.24</td>
<td>$0.35</td>
<td>-3.19%</td>
</tr>
<tr>
<td>Bruker Corp</td>
<td>24.81</td>
<td>5.02</td>
<td>2.79</td>
<td>0.47%</td>
<td>$0.08</td>
<td>$0.38</td>
<td>17.42%</td>
</tr>
<tr>
<td>Stevanato Group SpA</td>
<td>39.22</td>
<td>4.39</td>
<td>4.43</td>
<td>1.55%</td>
<td>$0.05</td>
<td>$0.07</td>
<td>1.67%</td>
</tr>
<tr>
<td>Sotera Health Co</td>
<td>113.29</td>
<td>10.62</td>
<td>4.10</td>
<td>2.05%</td>
<td>$0.1</td>
<td>$0.15</td>
<td>8.35%</td>
</tr>
<tr>
<td>Average</td>
<td>46.64</td>
<td>6.4</td>
<td>5.11</td>
<td>3.81%</td>
<td>$0.44</td>
<td>$0.73</td>
<td>2.11%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Upon a comprehensive analysis of Danaher, the following trends can be discerned: 
<ul>
<li>
The Price to Earnings ratio of 46.75 for this company is 1.0x above the industry average, indicating a premium valuation associated with the stock.
</li>
<li>
With a Price to Book ratio of 3.49, significantly falling below the industry average by 0.55x, it suggests undervaluation and the possibility of untapped growth prospects.
</li>
<li>
The stock's relatively high Price to Sales ratio of 7.74, surpassing the industry average by 1.51x, may indicate an aspect of overvaluation in terms of sales performance.
</li>
<li>
The company has a lower Return on Equity (ROE) of 1.62%, which is 2.19% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
With higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $1.66 Billion, which is 3.77x above the industry average, the company demonstrates stronger profitability and robust cash flow generation.
</li>
<li>
Compared to its industry, the company has higher gross profit of $3.4 Billion, which indicates 4.66x above the industry average, indicating stronger profitability and higher earnings from its core operations.
</li>
<li>
The company is experiencing remarkable revenue growth, with a rate of 3.09%, outperforming the industry average of 2.11%.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730732622_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When assessing Danaher against its top 4 peers using the Debt-to-Equity ratio, the following comparisons can be made:
<ul>
<li>
Danaher exhibits a stronger financial position compared to its top 4 peers in the sector, as indicated by its lower debt-to-equity ratio of 0.34.
</li>
<li>
This suggests that the company has a more favorable balance between debt and equity, which can be seen as a positive aspect for investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Danaher in the Life Sciences Tools &amp; Services industry, the PE ratio is high compared to peers, indicating potential overvaluation. The PB ratio is low, suggesting a possible undervaluation relative to industry standards. The PS ratio is high, signaling a premium valuation based on sales. In terms of ROE, Danaher shows lower profitability compared to peers. However, its high EBITDA, gross profit, and revenue growth reflect strong operational performance within the industry sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Inquiry Into Danaher's Competitor Dynamics In Life Sciences Tools &amp; Services Industry

In the current market session, Danaher Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) share price is at $242.91, after a 0.09% spike. Moreover, over the past month, the stock decreased by 8.25%, but in the past year, went up by 26.72%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1730491548_0.png" alt="Past Year Chart" />

<h3>Danaher P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Danaher has a better P/E ratio of 45.79 than the aggregate P/E ratio of 43.15 of the Life Sciences Tools &amp; Services industry. Ideally, one might believe that Danaher Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730491548_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Danaher Inc's Price Over Earnings

Wolfe Research analyst Doug Schenkel upgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Peer Perform to Outperform and announces $285 price target.

Upgrades

Price Target

Analyst Ratings

Wolfe Research Upgrades Danaher to Outperform, Announces $285 Price Target

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 5.16% on an annualized basis producing an average annual return of 16.37%. Currently, Danaher has a market capitalization of $176.82 billion. 
Buying $1000 In DHR: If an investor had bought $1000 of DHR stock 10 years ago, it would be worth $4,556.76 today based on a price of $244.81 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730129417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,600 Today

RBC Capital analyst Conor McNamara maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $333 to $311.

RBC Capital Maintains Outperform on Danaher, Lowers Price Target to $311

TD Cowen analyst Dan Brennan maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and raises the price target from $310 to $315.

TD Cowen Maintains Buy on Danaher, Raises Price Target to $315

Stephens &amp; Co. analyst Jacob Johnson reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Overweight and maintains $315 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Danaher, Maintains $315 Price Target

Stifel analyst Daniel Arias maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Hold and raises the price target from $250 to $265.

Stifel Maintains Hold on Danaher, Raises Price Target to $265

UBS analyst Dan Leonard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $309 to $305.

UBS Maintains Buy on Danaher, Lowers Price Target to $305

Raymond James analyst Andrew Cooper maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $310 to $300.

Raymond James Maintains Outperform on Danaher, Lowers Price Target to $300

Keybanc analyst Paul Knight maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Overweight and raises the price target from $290 to $310.

Keybanc Maintains Overweight on Danaher, Raises Price Target to $310

Barclays analyst Luke Sergott maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Equal-Weight and lowers the price target from $285 to $275.

Barclays Maintains Equal-Weight on Danaher, Lowers Price Target to $275

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Danaher, presenting an average target of $290.0, a high estimate of $315.00, and a low estimate of $277.00. This current average has increased by 1.99% from the previous average price target of $284.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1729684856_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Danaher by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$277.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$278.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$315.00</td>
<td>-</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$280.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Danaher. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Danaher compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Danaher's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Danaher's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Danaher analyst ratings.</a>
<h2>Unveiling the Story Behind Danaher</h2>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divesititure of its environmental and applied solutions group, Veralto.
<h3>Danaher: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Danaher's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -2.86% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Danaher's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.79% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Danaher's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.76% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Danaher's ROA excels beyond industry benchmarks, reaching 1.12%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Danaher Analyst Ratings: What You Need To Know

Baird analyst Catherine Schulte maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and lowers the price target from $278 to $277.

Baird Maintains Outperform on Danaher, Lowers Price Target to $277

On Tuesday,&nbsp;Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41449367/life-science-giant-danaher-q3-earnings-revenue-and-eps-beat-sticks-to-annual-guidance" rel="noreferrer noopener">consensus of $5.59 billion</a>.&nbsp;
Guidance: Danaher reaffirms that in fiscal year 2024, non-GAAP core revenue will be down in the low single digits year over year.
The company forecasts that 2024 bioprocessing core revenue will decline in the low single digits, and Cepheid 2024 respiratory revenues will be around&nbsp;$1.7 billion compared to prior guidance of $1.6 billion.
William Blair reports that Danaher&#8217;s third-quarter earnings aligned with expectations, particularly regarding the ongoing recovery in bioprocessing, though capital expenditures remain weak.
The analyst highlights that the recovery theme is progressing as anticipated, with results reflecting similar trends seen in industry conference updates earlier in the quarter.
Third-quarter book-to-bill improved to approximately 1.0x, up from 0.80x a year ago, and a high-single-digit increase in sequential orders further supported the bioprocessing rebound.
In the equipment segment, life sciences instruments saw a mid-single-digit decline, in line with forecasts and intra-quarter observations.
Meanwhile, diagnostics performed well, and Cepheid&#8217;s respiratory revenue again exceeded expectations.
On guidance, management expects mid- to high-single-digit core growth in the fourth quarter in Biotechnology. The analyst expects the focus of the call will be on the fourth-quarter exit rate for bioprocessing, any initial insights into 2025, capital equipment weakness, and updated thoughts on China.
William Blair keeps the Outperform rating. Goldman Sachs maintains a Neutral rating,<a href="https://www.benzinga.com/quote/dhr/analyst-ratings"> with a price target of $250.</a>
Price Action: DHR stock is down 4.01% at $261.18 at last check Tuesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462205/with-fda-approval-irhythm-may-be-able-to-lift-regulatory-overhang-investor-skeptici" target="_blank" rel="noreferrer noopener">With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says</a>.</li>
</ul>

Analyst Color

Earnings

Equities

Guidance

Health Care

General

Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating

Fidelity Select Health Care Portfolio Q3 2024 Fund Review

JPMorgan's 'Analyst Focus List' – growth, income, value, short ideas

SA Charts: These S&P 500 companies spent the largest on buybacks last quarter

BlackRock Event Driven Equity Fund Q3 2024 Commentary

Tracking Akre Capital Management Portfolio - Q3 2024 Update

Franklin DynaTech Fund Q3 2024 Commentary

Franklin DynaTech SMA Q3 2024 Commentary

Franklin U.S. Focused Growth SMA Q3 2024 Commentary

Tracking Al Gore's Generation Investment Management Portfolio - Q3 2024 Update

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

ABBV

ADBE

AGCO

ALNY

ALRM

AMAT

ARGNF

ARGX

ARMK

ASML

ASND

AVGO

AXON

BAMGF

BAMKF

BKAMF

BKFAF

BKFDF

BKFOF

BKFPF

BRBR

BRCFF

BROXF

BRPSF

BXDIF

CBRE

CCCS

CDNS

CLVT

CNSWF

CPRI

CSGP

CTLT

CVNA

CYBR

DAWN

DELL

DKNG

EWTX

EXAS

GOOG

GOOGL

GWRE

HSIC

HTHT

HUBS

INTC

INTU

ISRG

KLAC

KVUE

LEGN

LRCX

MELI

MNDY

MNST

MPWR

NISTF

NONOF

NPSCY

NTNX

NTRA

NVDA

NVST

ORLY

PCVX

PODD

RELY

ROIV

RVMD

SBAC

SCHW

SIRI

SNDX

SNPS

SOPH

SPGI

SWTX

TFII

TMUS

TOST

TRGP

TRMB

TSMWF

TVTX

TWLO

TYGO

ULTA

VEEV

VERA

VICI

VLTO

VRSK

WDAY

XENE

XLRE

Press Releases

Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening

Danaher Releases 2024 Sustainability Report

Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development

Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration

Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.

Danaher Confirms Third Quarter and Full Year 2024 Guidance

Dividends

Danaher Announces Quarterly Dividend

Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership

Danaher Schedules Third Quarter 2024 Earnings Conference Call

Danaher Reports Third Quarter 2024 Results

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Cytek Biosciences

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Danaher

ニュース

最新ニュース Danaher (NYSE:DHR) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル